1,3,5-trichlorobenzene

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2021

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Justification for type of information:

Study performed according to OECD 423 Guideline under GLP conditions.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2021

Report date:

2021

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1,3,5-trichlorobenzene

EC Number:

203-608-6

EC Name:

1,3,5-trichlorobenzene

Cas Number:

108-70-3

Molecular formula:

C6H3Cl3

IUPAC Name:

1,3,5-trichlorobenzene

Test material form:

solid

Details on test material:

• Sponsor’s identification: TCB (1,3,5-trichlorobenzène)
• Batch No.: 171882
• Category: Chemical Substance
• Date received: 17 September 2021
• EINECS No.: 203-608-6
• Container: plastic flask (n=1)
• CAS No : 108-70-3
• Quantity: 101.00 g (container + content + label)
• Form: solid
• Homogeneity: yes • Colour: white
• Production date: not provided
• Expiry date: February 2024
• Storage: room temperature
• Purity: 99,85 %
• Stability: stable under storage conditions
• Composition : 99.85 % 1,3,5-trichlorobenzène

Test animals

Species:

rat

Strain:

Sprague-Dawley

Sex:

female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

vegetable oil

Remarks:

olive oil

Doses:

4 groups of 3 rats exposed to 300 mg/kg and 2000 mg/kg

No. of animals per sex per dose:

6 rats exposed to 300 mg/kg and 6 rats exposed to 2000 mg/kg

Details on study design:

The standard study plan related to this study was approved by the registered Ethics Committee No. 76.

Results and discussion

Effect levels

Sex:

female

Dose descriptor:

LD50

Effect level:

5 000 mg/kg bw

Based on:

test mat.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

The LD50 of the test item TCB (1,3,5-trichlorobenzène) is higher than 2000 mg/kg body weight.
In accordance with the O.E.C.D. Test Guideline No. 423, the LD50 cut-off of the test item may be
considered as 5000 mg/kg body weight by oral route in the rat.
The test item TCB (1,3,5-trichlorobenzène) does not have to be classified in accordance with the
Regulation EC No. 1272/2008 on classification, labelling and packaging of substances and mixtures.
No signal word or hazard statement is required.

Executive summary:

Group treated at 300 mg/kg body weight:
One mortality (1/6) was noted in animals treated at 300 mg/kg body weight. This mortality was noted
5 min after the treatment with the test item. It is suspected a gavage injury.
Rigor mortis was noted before the necropsy.
The necropsy did not reveal treatment related changes.
In surviving animals (5/6), no clinical signs related to the administration of the test item were observed
during the study.
The body weight evolution of the animals remained normal during the study.
The macroscopic examination of the animals at the end of the study did not reveal treatment related
changes.
Group treated at 2000 mg/kg body weight:
No mortality was noted in animals treated at 2000 mg/kg body weight.
A decrease in spontaneous activity (2/6) and eyes partly closed (3/6) were noted at 1-hour and 3-hour
post-dose. An increase of salivation (2/6) was also noted at 30 minutes and 1-hour post-dose.
The body weight evolution of the animals remained normal during the study.
The macroscopic examination of the animals at the end of the study revealed a thin proventricular wall
(1/6) and fundic wall disintegrating when touched (3/6).